Article ID Journal Published Year Pages File Type
2827872 Blood Cells, Molecules, and Diseases 2011 5 Pages PDF
Abstract

Gaucher disease (GD) is a lysosomal storage disorder, caused by deficient activity of the enzyme glucocerebrosidase, which can be treated by enzyme-replacement therapy (ERT). No prognostic marker can predict long-term complications of GD but several markers are used in therapeutic monitoring: chitotriosidase, total serum ferritin (TSF), angiotensin-converting enzyme (ACE) and tartrate-resistant acid phosphatase (TRAP). They all increase with disease progression and generally decrease under ERT. This study was undertaken to investigate ferritin glycoforms, i.e., glycosylated ferritin (GF) and non-glycosylated ferritin (NGF) concentrations, as potential markers for the follow-up of GD therapy.GF and NGF determinations for GD patients followed in a single center between 1996 and 2007 were analyzed using two approaches: (1) the serum levels of 12 untreated patients were compared with those of 10 patients after 48 months on ERT; (2) the evolution of serum levels under ERT in 15 patients were analyzed using linear/logarithmic mixed models.TSF and NGF levels did not differed significantly between untreated patients and those on ERT (TSF: 524.5 (range 221.0–2045.0) μg/L vs. 410.5 (range 115.0–1587.0) μg/L, respectively, p = 0.72; NGF: 340.0 (range 182.8–1717.8) μg/L vs. 199.9 (range 77.1–649.8) μg/L, p = 0.09). The percent GF was significantly lower in untreated patients than in those on ERT (27.0% (range 8.0–51.0) vs. 43.5% (range 22.0–80.0) respectively; p = 0.02).The percent GF increased significantly during ERT (slope = 0.156% [95% confidence interval (CI), 0.03; 0.29] per month, p = 0.01) regardless of whether NGF and TSF significantly decreased during ERT (slope = −1.4% per month [95%CI, −1.9%; −1.0%], p < 0.0001; slope = –1.1% [95%CI, −1.6%; −0.6%] per month, p < 0.0007, respectively).Thus, GF is low in untreated GD patients. GF and NGF changed significantly under ERT and might be of clinical value for GD management under treatment.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology
Authors
, , , , , , , , ,